ARV110 is a bifunctional compound (PROTAC). It binds to the androgen receptor at one end and cereblon E3 ligase at the other end, and is an orally active specific androgen receptor (AR) PROTAC degrader. It has clinical potential as an oral therapy for metastatic castration-resistant prostate cancer. These pharmacokinetic findings are beneficial for future preclinical and clinical studies of ARV-110 and/or other PROTACs.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.